Cost-effectiveness of stepped care compared to continuous glucose monitoring in hypoglycemia-prone individuals with type 1 diabetes
Diabetes Epidemiology and Management · 2026 · 21 · 100319
DOI: 10.1016/j.deman.2026.100319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Epidemiology and Management, 2026. Verfasst von Milena Jancev und 7 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Health Research and Development.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To assess the cost-effectiveness of stepped care (education program plus continuous glucose monitoring (CGM) as needed), compared to immediate CGM use.
Methods
Analyses were conducted from a societal perspective over a 12-month horizon. Data were used from the Ecspect-Hypo randomized clinical trial, including 52 individuals with type 1 diabetes (T1D) and impaired hypoglycemia-awareness or a history of recent severe hypoglycemic events (SHEs) (mean age 53 years; 56% female). Outcomes included self-reported SHEs, quality-adjusted life years (QALYs) based on the EuroQol questionnaire, and costs were assessed using Tic-P questionnaires. Incremental cost-effectiveness ratios (ICERs) were calculated and cost-effectiveness acceptability curves were estimated.
Results
After 12 months, stepped care resulted in more SHEs (mean difference 0.33, 95%CI 0.056;0.60), less QALYs (mean difference -0.12, 95%CI -0.23;-0.0045), and lower societal costs (mean difference €-252, 95%CI -921;656) compared to CGM. The ICER per prevented SHE was €769, and per QALY gained €5518. The probability that stepped care was cost-effective compared to CGM use was 0.73 at a willingness to pay (WTP) of €0/SHE prevented and per individual with restored hypoglycemia-awareness, and 0.14 at €20,000/QALY gained.
Conclusions
Over 12 months, at a WTP threshold of €20,000/QALY, stepped care was not cost-effective compared to immediate CGM use in hypoglycemia-prone individuals with T1D.
Förderung
- Netherlands Organisation for Health Research and Development
Zitieren
APA
Jancev, M., Serné, E. H., Valk, H. W. D., DeVries, J. H., Sloten, T. V., Snoek, F. J., Wit, M. D., & Bosmans, J. E. (2026). Cost-effectiveness of stepped care compared to continuous glucose monitoring in hypoglycemia-prone individuals with type 1 diabetes. Diabetes Epidemiology and Management, 21, 100319. https://doi.org/10.1016/j.deman.2026.100319
Vancouver
Jancev M, Serné EH, Valk HWD, DeVries JH, Sloten TV, Snoek FJ, et al. Cost-effectiveness of stepped care compared to continuous glucose monitoring in hypoglycemia-prone individuals with type 1 diabetes. Diabetes Epidemiology and Management. 2026;21:100319. doi:10.1016/j.deman.2026.100319
BibTeX
@article{Jancev2026,
author = {Jancev, Milena and Serné, Erik H. and Valk, Harold W. de and DeVries, J. Hans and Sloten, Thomas van and Snoek, Frank J. and Wit, Maartje de and Bosmans, Judith E.},
title = {Cost-effectiveness of stepped care compared to continuous glucose monitoring in hypoglycemia-prone individuals with type 1 diabetes},
journal = {Diabetes Epidemiology and Management},
year = {2026},
volume = {21},
pages = {100319},
doi = {10.1016/j.deman.2026.100319}
}
EUVIMED